The physiology and pathophysiology of the osteoclast

Clinical Reviews in Bone and Mineral Metabolism

Volumn 10, Issue 2, 2012, Pages 71-97

  Peruzzi, Barbara ^a,b   Teti, Anna ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Bone remodeling; Bone resorption; Osteoclast; Osteopetrosis; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACTIVATING TRANSCRIPTION FACTOR 2; ADENOSINE TRIPHOSPHATE; BONE MORPHOGENETIC PROTEIN; CARBONATE DEHYDRATASE II; CATHEPSIN K; CD147 ANTIGEN; COLONY STIMULATING FACTOR 1; CYCLIC AMP; CYCLIN DEPENDENT KINASE; FAS LIGAND; FOCAL ADHESION KINASE; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN ENHANCER BINDING FACTOR 2; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E2; SOMATOMEDIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNINDEXED DRUG;

ALBERS SCHOENBERG DISEASE; ARTICLE; BONE DISEASE; BONE MATRIX; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; CELL STRUCTURE; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOASSAY; IN VITRO STUDY; INTERSTITIAL FLUID; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSCYTOSIS; Y CHROMOSOMAL INHERITANCE;

EID: 84861228115     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-011-9086-6     Document Type: Article

References (275)

1. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170:427-35. (Pubitemid 47339379)
2. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285:25103-8.
3. Sommerfeldt DW, Rubin CT. Biology of bone and how it orchestrates the form and function of the skeleton. Eur Spine J. 2001;10(Suppl 2):S86-95.
4. Fukumoto S. Chronic kidney disease (CKD) and bone. Regulation of calcium and phosphate metabolism by FGF23/Klotho. Clin Calcium. 2009;19:523-8.
5. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456-69. (Pubitemid 47208519)
6. Garrett RW, Emerson SG. The role of parathyroid hormone and insulin-like growth factors in hematopoietic niches: physiology and pharmacology. Mol Cell Endocrinol. 2008;288:6-10.
7. Ferron M, Wei J, Yoshizawa T, Del Fattore A, De Pinho RA, Teti A, Ducy P, Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142:296-308.
8. George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, Bhatia SJ, Shah S, Menon PS, Shah N. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol. 2009;15:3516-22.
9. Santangelo A, Testai M, Mamazza G, Zuccaro C, Albani S, Pavano S, Cappello A, Sambataro D, Atteritano M, Maugeri D. The bone mass (BM) and chronic cardiac decompensation (CCD) in an elderly population. Arch Gerontol Geriatr. 2010 May 26 [Epub ahead of print].
10. Nikolov IG, Joki N, Nguyen-Khoa T, Ivanovski O, Phan O, Lacour B, Drueke TB, Massy ZA, Dos Reis LM, Jorgetti V, Lafage-Proust MH. Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure. Bone. 2010;47:156-63.
11. Teti A, Eastell R, Eds. The central role of the skeleton in chronic diseases. Arch Biochem Biophys. 2010;503:1-160.
12. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev. 1996;17:308-32. (Pubitemid 26277978)
13. Stenbeck G. Formation and function of the ruffled border in osteoclasts. Semin Cell Dev Biol. 2002;13:285-92. (Pubitemid 35304514)
14. Takahashi N, Ejiri S, Yanagisawa S, Ozawa H. Regulation of osteoclast polarization. Odontology. 2007;95:1-9.
15. Coxon FP, Taylor A. Vesicular trafficking in osteoclasts. Semin Cell Dev Biol. 2008;19:424-33.
16. Andersson G, Ek-Rylander B, Hollberg K, Ljusberg-Sjolander J, Lang P, Norgard M, Wang Y, Zhang SJ. TRACP as an osteopontin phosphatase. J Bone Miner Res. 2003;18:1912-5. (Pubitemid 37322574)
17. Mitic N, Valizadeh M, Leung EW, de Jersey J, Hamilton S, Hume DA, Cassady AI, Schenk G. Human tartrate-resistant acid phosphatase becomes an effective ATPase upon proteolytic activation. Arch Biochem Biophys. 2005;439:154-64. (Pubitemid 40922701)
18. Suter A, Everts V, Boyde A, Jones SJ, Lullmann-Rauch R, Hartmann D, Hayman AR, Cox TM, Evans MJ, Meister T, von Figura K, Saftig P. Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice. Development. 2001;128:4899-910. (Pubitemid 33138599)
19. Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y, De Laet C, Hubner CA, Meinecke P, Nishimura G, Matsuo M, Hirano Y, Tenoutasse S, Kiss A, Machado Rosa RF, Unger SL, Renella R, Bonafe L, Spranger J, Unger S, Zabel B, Superti-Furga A. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet. 2011;43:132-7.
20. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaisse JM. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273:32347-52. (Pubitemid 29177183)
21. Nielsen RH, Karsdal MA, Sorensen MG, Dziegiel MH, Henriksen K. Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival. Biochem Biophys Res Commun. 2007;360:834-9. (Pubitemid 47077396)
22. Baron R, Neff L, Brown W, Courtoy PJ, Louvard D, Farquhar MG. Polarized secretion of lysosomal enzymes: co-distribution of cation-independent mannose-6-phosphate receptors and lysosomal enzymes along the osteoclast exocytic pathway. J Cell Biol. 1988;106:1863-72.
23. Miyazaki T, Tanaka S, Sanjay A, Baron R. The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol. 2006;16:68-74.
24. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med. 2004;2:6.
25. Sugiyama T, Kusuhara S. The kinetics of actin filaments in osteoclasts on chicken medullary bone during the egg-laying cycle. Bone. 1994;15:351-3.
26. Bird MC, Garside D, Jones HB. Multinucleated giant cells in primary cultures derived from canine bone marrow-evidence for formation of putative osteoclasts. Cell Tissue Res. 1992;268:17-30.
27. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev. 1992;13:66-80.
28. Sakiyama H, Masuda R, Inoue N, Yamamoto K, Kuriiwa K, Nakagawa K, Yoshida K. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. J Bone Miner Metab. 2001;19:220-7. (Pubitemid 32681379)
29. Akisaka T, Yoshida H, Inoue S, Shimizu K. Organization of cytoskeletal F-actin, G-actin, and gelsolin in the adhesion structures in cultured osteoclast. J Bone Miner Res. 2001;16:1248-55. (Pubitemid 32574653)
30. Marchisio PC, Cirillo D, Naldini L, Primavera MV, Teti A, Zambonin-Zallone A. Cell-substratum interaction of cultured avian osteoclasts is mediated by specific adhesion structures. J Cell Biol. 1984;99:1696-705. (Pubitemid 15223606)
31. Nakamura I, Duong IT, Rodan SB, Rodan GA. Involvement of alpha (v) beta3 integrins in osteoclast function. J Bone Miner Metab. 2007;25:337-44. (Pubitemid 350063834)
32. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100-3. (Pubitemid 30056702)
33. Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int. 2007;18:681-5. (Pubitemid 46525540)
34. Siva NAG, Visweswara PR, Dhananjaya MN, Ramesh VC, Jagadesh G, Narasaiah VT. Clinical importance of SERUM TRAP-5b and UrineCTX-I in the assessment of bone loss in postmenopausal women. Int J Biotechnol Biochem. 2010;6:427-34.
35. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52:499-509. (Pubitemid 44649680)
36. Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res. 1988;175:266-76.
37. Teti A, Blair HC, Teitelbaum SL, Kahn AJ, Koziol C, Konsek J, Zambonin-Zallone A, Schlesinger PH. Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J Clin Invest. 1989;83:227-33. (Pubitemid 19048428)
38. Baron R. Polarity and membrane transport in osteoclasts. Connect Tissue Res. 1989;20:109-20.
39. Blair HC, Kahn AJ, Crouch EC, Jeffrey JJ, Teitelbaum SL. Isolated osteoclasts resorb the organic and inorganic components of bone. J Cell Biol. 1986;102:1164-72. (Pubitemid 16038060)
40. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 1996;271:12517-24. (Pubitemid 26160924)
41. Everts V, Delaisse JM, Korper W, Niehof A, Vaes G, Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol. 1992;150:221-31.
42. Vaananen HK, Iu YK, Lehenkari P, Uemara T. How do osteoclasts resorb bone? Mat Sci Eng C. 1998;6:205-9. (Pubitemid 128421827)
43. Zhao H, Ettala O, Vaananen HK. Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTPbinding rab proteins. Biochem Biophys Res Commun. 2002;293:1060-5. (Pubitemid 34694149)
44. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science. 1997;276:266-9. (Pubitemid 27172687)
45. Salo J, Lehenkari P, Mulari M, Metsikko K, Vaananen HK. Removal of osteoclast bone resorption products by transcytosis. Science. 1997;276:270-3. (Pubitemid 27172688)
46. Coxon FP, Rogers MJ. The role of prenylated small GTPbinding proteins in the regulation of osteoclast function. Calcif Tissue Int. 2003;72:80-4. (Pubitemid 36918941)
47. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119(Suppl 2):S150-62. (Pubitemid 46397937)
48. Teti A, Marchisio PC, Zallone AZ. Clear zone in osteoclast function: role of podosomes in regulation of bone-resorbing activity. Am J Physiol. 1991;261:C1-7.
49. Grano M, Faccio R, Colucci S, Paniccia R, Baldini N, Zallone AZ, Teti A. Extracellular Ca2+ sensing is modulated by pH in human osteoclast-like cells in vitro. Am J Physiol. 1994;267:C961-8.
50. Marks SC Jr, Walker DG. The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors. Am J Anat. 1981;161:1-10. (Pubitemid 11104658)
51. Walker DG. Control of bone resorption by hematopoietic tissue. The induction and reversal of congenital osteopetrosis in mice through use of bone marrow and splenic transplants. J Exp Med. 1975;142:651-63.
52. Coccia PF, Krivit W, Cervenka J, Clawson C, Kersey JH, Kim TH, Nesbit ME, Ramsay NK, Warkentin PI, Teitelbaum SL, Kahn AJ, Brown DM. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med. 1980;302:701-8. (Pubitemid 10132096)
53. Driessen GJ, Gerritsen EJ, Fischer A, Fasth A, Hop WC, Veys P, Porta F, Cant A, Steward CG, Vossen JM, Uckan D, Friedrich W. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant. 2003;32:657-63. (Pubitemid 37258621)
54. Teitelbaum SL, Tondravi MM, Ross FP. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leukoc Biol. 1997;61:381-8. (Pubitemid 27219830)
55. Yavropoulou MP, Yovos JG. Osteoclastogenesis-current knowledge and future perspectives. J Musculoskelet Neuronal Interact. 2008;8:204-16.
56. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, Teitelbaum SL. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature. 1997;386:81-4. (Pubitemid 27130924)
57. Hayashi S, Yamane T, Miyamoto A, Hemmi H, Tagaya H, Tanio Y, Kanda H, Yamazaki H, Kunisada T. Commitment and differentiation of stem cells to the osteoclast lineage. Biochem Cell Biol. 1998;76:911-22. (Pubitemid 29450560)
58. Mundy GR. Cytokines and growth factors in the regulation of bone remodeling. J Bone Miner Res. 1993;8(Suppl 2):S505-10. (Pubitemid 24015239)
59. Fleisch H, Hofstetter W, Felix R, Cecchini M, Wetterwald A. The role of macrophage stimulating factor M-CSF in bone resorption. Osteoporos Int. 1993;3(Suppl 1):108-10. (Pubitemid 23099905)
60. Ross FP. M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann N Y Acad Sci. 2006;1068:110-6. (Pubitemid 43824142)
61. So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, Choi Y, Kim N. Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem. 2003;278:24209-16. (Pubitemid 36830257)
62. Kwon OH, Lee CK, Lee YI, Paik SG, Lee HJ. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. Biochem Biophys Res Commun. 2005;335:437-46.
63. Meadows NA, Sharma SM, Faulkner GJ, Ostrowski MC, Hume DA, Cassady AI. The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor. J Biol Chem. 2007;282:1891-904. (Pubitemid 47076682)
64. Wagner EF, Matsuo K. Signalling in osteoclasts and the role of Fos/AP1 proteins. Ann Rheum Dis. 2003;62(Suppl 2):ii83-5.
65. Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev. 2005;208:181-93. (Pubitemid 41746393)
66. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-23.
67. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKLRANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17-25. (Pubitemid 43089652)
68. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci. 2007;1116:227-37. (Pubitemid 350274348)
69. Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colonystimulating factor suppression of osteoclast formation. J Biol Chem. 2005;280:16163-9. (Pubitemid 40616742)
70. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med. 2006;12:1403-9. (Pubitemid 44924499)
71. Kim K, Lee SH, Ha KJ, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 2008;22:176-85.
72. Paniccia R, Colucci S, Grano M, Serra M, Zallone AZ, Teti A. Immediate cell signal by bone-related peptides in human osteoclast-like cells. Am J Physiol. 1993;265:C1289-97.
73. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, Zambonin-Zallone A, Ross FP, Teitelbaum SL, Cheresh D. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem. 1991;266:20369-74. (Pubitemid 21908468)
74. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995;268:233-9.
75. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007;176:877-88. (Pubitemid 46425547)
76. Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol. 1998;25:1282-9. (Pubitemid 28312343)
77. Wiebe SH, Hafezi M, Sandhu HS, Sims SM, Dixon SJ. Osteoclast activation in inflammatory periodontal diseases. Oral Dis. 1996;2:167-80. (Pubitemid 26310907)
78. De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P, Ferrari S, Teti A. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006;54:3551-63. (Pubitemid 44737167)
79. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-33. (Pubitemid 27093099)
80. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006;116:1186-94.
81. Nemeth K, Schoppet M, Al Fakhri N, Helas S, Jessberger R, Hofbauer LC, Goettsch C. The role of osteoclast-associated receptor in osteoimmunology. J Immunol. 2011;186:13-8.
82. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412-24. (Pubitemid 29453612)
83. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008;83:64-76. (Pubitemid 351916706)
84. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39:960-2. (Pubitemid 47185178)
85. Li JY, Tawfeek H, Bedi B, Yang X, Adams J, Gao KY, Zayzafoon M, Weitzmann MN, Pacifici R. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci U S A. 2011;108:768-73.
86. Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum. 2005;52:2307-12. (Pubitemid 41117414)
87. Mirosavljevic D, Quinn JM, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res. 2003;18:984-93. (Pubitemid 37294934)
88. Nakashima T, Takayanagi H. The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys. 2008;473:166-71.
89. Adamopoulos IE, Bowman EP. Immune regulation of bone loss by Th17 cells. Arthritis Res Ther. 2008;10:225.
90. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2001;15:677-91. (Pubitemid 34092508)
91. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203:2673-82. (Pubitemid 44833343)
92. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collageninduced arthritis in rats. Arthritis Res Ther. 2007;9:R96.
93. Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, Kotake S. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem. 2009;108:947-55.
94. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Berg L, Helsen MM, Di Padova FE, Boots AM, Gram H, Joosten LA, van den Berg WB. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005;167:141-9. (Pubitemid 40884777)
95. Okamoto K, Takayanagi H. Osteoclasts in arthritis and Th17 cell development. Int Immunopharmacol. 2010.
96. Horowitz MC, Fretz JA, Lorenzo JA. How B cells influence bone biology in health and disease. Bone. 2010;47:472-9.
97. Xiao P, Chen Y, Jiang H, Liu YZ, Pan F, Yang TL, Tang ZH, Larsen JA, Lappe JM, Recker RR, Deng HW. In vivo genomewide expression study on human circulating B cells suggests a novel ESR1 and MAPK3 network for postmenopausal osteoporosis. J Bone Miner Res. 2008;23:644-54. (Pubitemid 351575018)
98. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007;109:3839-48. (Pubitemid 46641735)
99. Kato I, Sato H, Kudo A. TRANCE together with IL-7 induces pre-B cells to proliferate. Eur J Immunol. 2003;33:334-41. (Pubitemid 36267597)
100. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Nabeshima Y, Nakamura K, Sinclair AM, Scheuermann RH, Kuro-o M. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol. 2001;167:2625-31. (Pubitemid 32768891)
101. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res. 2002;57:385-409.
102. Seeman E. Estrogen, androgen, and the pathogenesis of bone fragility in women and men. Curr Osteoporos Rep. 2004;2:90-6.
103. Vandenput L, Ohlsson C. Estrogens as regulators of bone health in men. Nat Rev Endocrinol. 2009;5:437-43.
104. Imai Y, Kondoh S, Kouzmenko A, Kato S. Minireview: osteoprotective action of estrogens is mediated by osteoclastic estrogen receptor-alpha. Mol Endocrinol. 2010;24:877-85.
105. Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005;20:2224-32. (Pubitemid 41698785)
106. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007;130:811-23. (Pubitemid 47332572)
107. Imai Y, Youn MY, Kondoh S, Nakamura T, Kouzmenko A, Matsumoto T, Takada I, Takaoka K, Kato S. Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad Sci. 2009;1173(Suppl 1):E31-9.
108. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol. 2003;177:423-33. (Pubitemid 36722298)
109. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883-91.
110. Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism. 1976;25:909-55.
111. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4-8. (Pubitemid 43831956)
112. Haussler MR, McCain TA. Basic and clinical concepts related to vitamin D metabolism and action (first of two parts). N Engl J Med. 1977;297:974-83. (Pubitemid 8218827)
113. Haussler MR, McCain TA. Basic and clinical concepts related to vitamin D metabolism and action (second of two parts). N Engl J Med. 1977;297:1041-50. (Pubitemid 8228328)
114. Takeda S, Yoshizawa T, Nagai Y, Yamato H, Fukumoto S, Sekine K, Kato S, Matsumoto T, Fujita T. Stimulation of osteoclast formation by 1, 25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology. 1999;140:1005-8. (Pubitemid 29058242)
115. Lee K, Deeds JD, Chiba S, Un-No M, Bond AT, Segre GV. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology. 1994;134:441-50. (Pubitemid 24022023)
116. Martin TJ, Ng KW. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J Cell Biochem. 1994;56:357-66. (Pubitemid 24360054)
117. Datta HK, MacIntyre I, Zaidi M. The effect of extracellular calcium elevation on morphology and function of isolated rat osteoclasts. Biosci Rep. 1989;9:747-51. (Pubitemid 20042054)
118. Malgaroli A, Meldolesi J, Zallone AZ, Teti A. Control of cytosolic free calcium in rat and chicken osteoclasts. The role of extracellular calcium and calcitonin. J Biol Chem. 1989;264:14342-7. (Pubitemid 19214264)
119. Zaidi M, Alam AS, Huang CL, Pazianas M, Bax CM, Bax BE, Moonga BS, Bevis PJ, Shankar VS. Extracellular Ca2+ sensing by the osteoclast. Cell Calcium. 1993;14:271-7.
120. Miyauchi A, Hruska KA, Greenfield EM, Duncan R, Alvarez J, Barattolo R, Colucci S, Zambonin-Zallone A, Teitelbaum SL, Teti A. Osteoclast cytosolic calcium, regulated by voltage-gated calcium channels and extracellular calcium, controls podosome assembly and bone resorption. J Cell Biol. 1990;111:2543-52. (Pubitemid 120014537)
121. Seuwen K, Boddeke HG, Migliaccio S, Perez M, Taranta A, Teti A. A novel calcium sensor stimulating inositol phosphate formation and [Ca2+]i signaling expressed by GCT23 osteoclastlike cells. Proc Assoc Am Physicians. 1999;111:70-81. (Pubitemid 29047112)
122. Moonga BS, Li S, Iqbal J, Davidson R, Shankar VS, Bevis PJ, Inzerillo A, Abe E, Huang CL, Zaidi M. Ca (2+) influx through the osteoclastic plasma membrane ryanodine receptor. Am J Physiol Renal Physiol. 2002;282:F921-32.
123. Biskobing DM, Fan D. Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts. Calcif Tissue Int. 2000;67:178-83. (Pubitemid 30614645)
124. Krieger NS, Frick KK, Bushinsky DA. Mechanism of acidinduced bone resorption. Curr Opin Nephrol Hypertens. 2004;13:423-36.
125. Muzylak M, Arnett TR, Price JS, Horton MA. The in vitro effect of pH on osteoclasts and bone resorption in the cat: implications for the pathogenesis of FORL. J Cell Physiol. 2007;213:144-50. (Pubitemid 47378802)
126. Arnett TR. Extracellular pH regulates bone cell function. J Nutr. 2008;138:415S-8S. (Pubitemid 351213661)
127. Iwai K, Koike M, Ohshima S, Miyatake K, Uchiyama Y, Saeki Y, Ishii M. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway. J Bone Miner Res. 2007;22:1612-20. (Pubitemid 351229331)
128. Pereverzev A, Komarova SV, Korcok J, Armstrong S, Tremblay GB, Dixon SJ, Sims SM. Extracellular acidification enhances osteoclast survival through an NFAT-independent, protein kinase C-dependent pathway. Bone. 2008;42:150-61. (Pubitemid 350297179)
129. Huang CL, Sun L, Moonga BS, Zaidi M. Molecular physiology and pharmacology of calcitonin. Cell Mol Biol. 2006;52:33-43.
130. Martinez A, Kapas S, Miller MJ, Ward Y, Cuttitta F. Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells. Endocrinology. 2000;141:406-11. (Pubitemid 32260383)
131. Carter PH, Schipani E. The roles of parathyroid hormone and calcitonin in bone remodeling: prospects for novel therapeutics. Endocr Metab Immune Disord Drug Targets. 2006;6:59-76. (Pubitemid 43803133)
132. Raisz LG, Niemann I. Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture. Endocrinology. 1969;85:446-52.
133. Yang M, Kream BE. Calcitonin induces expression of the inducible cAMP early repressor in osteoclasts. Endocrine. 2008;33:245-53.
134. Ikegame M, Ejiri S, Ozawa H. Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors. Bone. 2004;35:27-33. (Pubitemid 38789145)
135. Shyu JF, Shih C, Tseng CY, Lin CH, Sun DT, Liu HT, Tsung HC, Chen TH, Lu RB. Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities. Bone. 2007;40:1329-42. (Pubitemid 46550990)
136. Granholm S, Lundberg P, Lerner UH. Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J Cell Biochem. 2008;104:920-33. (Pubitemid 351830840)
137. Lee SK, Goldring SR, Lorenzo JA. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. Endocrinology. 1995;136:4572-81.
138. Dempster DW, Moonga BS, Stein LS, Horbert WR, Antakly T. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J Endocrinol. 1997;154:397-406. (Pubitemid 27375034)
139. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Patrick RF, Teitelbaum SL. Glucocorticoids and the osteoclast. Ann N Y Acad Sci. 2007;1116:335-9. (Pubitemid 350274339)
140. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89:4923-8. (Pubitemid 39391429)
141. Oreffo RO, Teti A, Triffitt JT, Francis MJ, Carano A, Zallone AZ. Effect of vitamin A on bone resorption: evidence for direct stimulation of isolated chicken osteoclasts by retinol and retinoic acid. J Bone Miner Res. 1988;3:203-10.
142. Saneshige S, Mano H, Tezuka K, Kakudo S, Mori Y, Honda Y, Itabashi A, Yamada T, Miyata K, Hakeda Y. Retinoic acid directly stimulates osteoclastic bone resorption and gene expression of cathepsin K/OC-2. Biochem J. 1995;309(Pt 3):721-4.
143. Bonewald LF, Oreffo RO, Lee CH, Park-Snyder S, Twardzik D, Mundy GR. Effects of retinol on activation of latent transforming growth factor-beta by isolated osteoclasts. Endocrinology. 1997;138:657-66. (Pubitemid 27110916)
144. Wang X, Wu J, Shidoji Y, Muto Y, Ohishi N, Yagi K, Ikegami S, Shinki T, Udagawa N, Suda T, Ishimi Y. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation. J Bone Miner Res. 2002;17:91-100. (Pubitemid 33151000)
145. Kawai M, Sousa KM, MacDougald OA, Rosen CJ. The many facets of PPARgamma: novel insights for the skeleton. Am J Physiol Endocrinol Metab. 2010;299:E3-9.
146. Wang S, El Deiry WS. TRAIL and apoptosis induction by TNFfamily death receptors. Oncogene. 2003;22:8628-33. (Pubitemid 38019198)
147. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148:2669-80. (Pubitemid 46984815)
148. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW. IL-4
149. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496-503.
150. Gronthos S, Zannettino AC. The role of the chemokine CXCL12 in osteoclastogenesis. Trends Endocrinol Metab. 2007;18:108-13. (Pubitemid 46453193)
151. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med. 2010;207:2793-8.
152. Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, Proia RL, Germain RN. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009;458:524-8.
153. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478-87.
154. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006;6:307-12. (Pubitemid 43670914)
155. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996;2:1132-6.
156. Feng X. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene. 2005;350:1-13.
157. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis. 2007;12:1623-32. (Pubitemid 47106894)
158. Villanova I, Townsend PA, Uhlmann E, Knolle J, Peyman A, Amling M, Baron R, Horton MA, Teti A. Oligodeoxynucleotide targeted to the alphav gene inhibits alphav integrin synthesis, impairs osteoclast function, and activates intracellular signals to apoptosis. J Bone Miner Res. 1999;14:1867-79. (Pubitemid 29521782)
159. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000;105:433-40. (Pubitemid 30127243)
160. Zhao H, Ross FP, Teitelbaum SL. Unoccupied alpha (v) beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol Endocrinol. 2005;19:771-80. (Pubitemid 40349447)
161. Inoue M, Namba N, Chappel J, Teitelbaum SL, Ross FP. Granulocyte macrophage-colony stimulating factor reciprocally regulates alphav-associated integrins on murine osteoclast precursors. Mol Endocrinol. 1998;12:1955-62.
162. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 2007;67:5821-30. (Pubitemid 46985016)
163. Duong LT, Lakkakorpi P, Nakamura I, Rodan GA. Integrins and signaling in osteoclast function. Matrix Biol. 2000;19:97-105. (Pubitemid 30332433)
164. Spinardi L, Marchisio PC. Podosomes as smart regulators of cellular adhesion. Eur J Cell Biol. 2006;85:191-4.
165. Zambonin-Zallone A, Teti A, Grano M, Rubinacci A, Abbadini M, Gaboli M, Marchisio PC. Immunocytochemical distribution of extracellular matrix receptors in human osteoclasts: a beta 3 integrin is colocalized with vinculin and talin in the podosomes of osteoclastoma giant cells. Exp Cell Res. 1989;182:645-52. (Pubitemid 19154082)
166. Jurdic P, Saltel F, Chabadel A, Destaing O. Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol. 2006;85:195-202.
167. Chellaiah MA. Regulation of podosomes by integrin alphavbeta3 and Rho GTPase-facilitated phosphoinositide signaling. Eur J Cell Biol. 2006;85:311-7.
168. Boyce BF, Yao Z, Xing L. Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr. 2009;19:171-80.
169. Del Fattore A, Fornari R, Van Wesenbeeck L, de Freitas F, Timmermans JP, Peruzzi B, Cappariello A, Rucci N, Spera G, Helfrich MH, Van Hul W, Migliaccio S, Teti A. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1(PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res. 2008;23:380-91. (Pubitemid 351304668)
170. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473:201-9.
171. Edwards CM, Mundy GR. Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci. 2008;5:263-72.
172. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836-41. (Pubitemid 37351467)
173. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841-6. (Pubitemid 37351468)
174. Kollet O, Dar A, Lapidot T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol. 2007;25:51-69. (Pubitemid 46697902)
175. Purton LE, Scadden DT. Osteoclasts eat stem cells out of house and home. Nat Med. 2006;12:610-1. (Pubitemid 43869937)
176. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Bruning JC, Clemens TL. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142:309-19.
177. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008;42:19-29. (Pubitemid 350297169)
178. Van Wesenbeeck L, Van Hul W. Lessons from osteopetrotic mutations in animals: impact on our current understanding of osteoclast biology. Crit Rev Eukaryot Gene Expr. 2005;15:133-62. (Pubitemid 41277408)
179. Van Hul W, Vanhoenacker F, Balemans W, Janssens K, De Schepper AM. Molecular and radiological diagnosis of sclerosing bone dysplasias. Eur J Radiol. 2001;40:198-207. (Pubitemid 33112019)
180. Smahi A, Courtois G, Rabia SH, Doffinger R, Bodemer C, Munnich A, Casanova JL, Israel A. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 2002;11:2371-5. (Pubitemid 35174700)
181. Villa A, Guerrini MM, Cassani B, Pangrazio A, Sobacchi C. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tissue Int. 2009;84:1-12.
182. Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature. 2006;440:220-3. (Pubitemid 43372100)
183. Campos-Xavier AB, Casanova JL, Doumaz Y, Feingold J, Munnich A, Cormier-Daire V. Intrafamilial phenotypic variability of osteopetrosis due to chloride channel 7 (CLCN7) mutations. Am J Med Genet A. 2005;133 A: 216-8. (Pubitemid 40279795)
184. Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M, Devito R, Pinto R, Caniglia M, Lanino E, Messina C, Cesaro S, Letizia C, Bianchini G, Fryssira H, Grabowski P, Shaw N, Bishop N, Hughes D, Kapur RP, Datta HK, Taranta A, Fornari R, Migliaccio S, Teti A. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet. 2006;43:315-25.
185. Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, Andolina M, Flanagan A, Horwitz EM, Mihci E, Notarangelo LD, Ramenghi U, Teti A, Van Hove J, Vujic D, Young T, Albertini A, Orchard PJ, Vezzoni P, Villa A. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res. 2003;18:1740-7. (Pubitemid 37322549)
186. Waguespack SG, Hui SL, Dimeglio LA, Econs MJ. Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab. 2007;92:771-8. (Pubitemid 46465639)
187. Kida E, Palminiello S, Golabek AA, Walus M, Wierzba-Bobrowicz T, Rabe A, Albertini G, Wisniewski KE. Carbonic anhydrase II in the developing and adult human brain. J Neuropathol Exp Neurol. 2006;65:664-74. (Pubitemid 44297257)
188. Borthwick KJ, Kandemir N, Topaloglu R, Kornak U, Bakkaloglu A, Yordam N, Ozen S, Mocan H, Shah GN, Sly WS, Karet FE. A phenocopy of CAII deficiency: a novel genetic explanation for inherited infantile osteopetrosis with distal renal tubular acidosis. J Med Genet. 2003;40:115-21. (Pubitemid 36232816)
189. Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, MacKay CA, Van Hul E, Timmermans JP, Vanhoenacker F, Jacobs R, Peruzzi B, Teti A, Helfrich MH, Rogers MJ, Villa A, Van Hul W. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007;117:919-30. (Pubitemid 46556748)
190. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis. 2002;61(Suppl 2):ii32-9. (Pubitemid 35221710)
191. Whyte MP. Osteopetrosis. In: Royce PM, Steinamann B, editors. Connective tissue and its heritable disorders: medical genetic and molecular aspects. New York: Wiley-Liss; 2011. p. 753-70.
192. Schinke T, Schilling AF, Baranowsky A, Seitz S, Marshall RP, Linn T, Blaeker M, Huebner AK, Schulz A, Simon R, Gebauer M, Priemel M, Kornak U, Perkovic S, Barvencik F, Beil FT, Del Fattore A, Frattini A, Streichert T, Pueschel K, Villa A, Debatin KM, Rueger JM, Teti A, Zustin J, Sauter G, Amling M. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med. 2009;15:674-81.
193. Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, Schmitt A, Poet M, Steinfeld R, Schweizer M, Kornak U, Jentsch TJ. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J. 2005;24:1079-91. (Pubitemid 40470155)
194. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273:1236-8.
195. Soliman AT, Ramadan MA, Sherif A, Aziz Bedair ES, Rizk MM. Pycnodysostosis: clinical, radiologic, and endocrine evaluation and linear growth after growth hormone therapy. Metabolism. 2001;50:905-11. (Pubitemid 32755006)
196. Laffranchi L, Dalessandri D, Tonni I, Paganelli C. Use of CBCT in the orthodontic diagnosis of a patient with pycnodysostosis. Minerva Stomatol. 2010;59:653-61.
197. Karakurt L, Yilmaz E, Belhan O, Serin E. Pycnodysostosis associated with bilateral congenital pseudarthrosis of the clavicle. Arch Orthop Trauma Surg. 2003;123:125-7. (Pubitemid 36748538)
198. Janssens K, de Vernejoul MC, de Freitas F, Vanhoenacker F, Van Hul W. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone. 2005;36:542-8. (Pubitemid 40403852)
199. Ooi CG, Fraser WD. Paget's disease of bone. Postgrad Med J. 1997;73:69-74. (Pubitemid 27092461)
200. Daroszewska A, Ralston SH. Genetics of Paget's disease of bone. Clin Sci (Lond). 2005;109:257-63. (Pubitemid 41337129)
201. Roodman GD. Insights into the pathogenesis of Paget's disease. Ann N Y Acad Sci. 2010;1192:176-80.
202. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008;372:155-63. (Pubitemid 351952259)
203. Kovacic N, Grcevic D, Katavic V, Lukic IK, Grubisic V, Mihovilovic K, Cvija H, Croucher PI, Marusic A. Fas receptor is required for estrogen deficiency-induced bone loss in mice. Lab Invest. 2010;90:402-13.
204. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 2008;27:535-45. (Pubitemid 351225684)
205. Glaser DL, Kaplan FS. Osteoporosis. Definition and clinical presentation. Spine. 1997;22:12S-6S.
206. Khosla S, Melton LJ III, Riggs BL. Osteoporosis: gender differences and similarities. Lupus. 1999;8:393-6. (Pubitemid 29378021)
207. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318-25. (Pubitemid 43121814)
208. Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:325-8. (Pubitemid 40873119)
209. Saidenberg KN, Bessis N, Cohen-Solal M, de Vernejoul MC, Boissier MC. Osteoprotegerin and inflammation. Eur Cytokine Netw. 2002;13:144-53. (Pubitemid 34752177)
210. Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005;43:973-83. (Pubitemid 41627982)
211. Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol. 2010;54:123-32.
212. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266-74. (Pubitemid 28503012)
213. Tamura Y, Okinaga H, Takami H. Glucocorticoid-induced osteoporosis. Biomed Pharmacother. 2004;58:500-4. (Pubitemid 39423597)
214. Tait AS, Butts CL, Sternberg EM. The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. J Leukoc Biol. 2008;84:924-31.
215. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835-41. (Pubitemid 38402392)
216. Vignery A, Baron R. Effects of parathyroid hormone on the osteoclastic pool, bone resorption and formation in rat alveolar bone. Calcif Tissue Res. 1978;26:23-8. (Pubitemid 9088825)
217. Jaworski ZF, Lok E, Wellington JL. Impaired osteoclastic function and linear bone erosion rate in secondary hyperparathyroidism associated with chronic renal failure. Clin Orthop Relat Res. 298-310
218. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology. 1999;140:3552-61. (Pubitemid 30645409)
219. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439-46. (Pubitemid 29534328)
220. Keyak JH, Koyama AK, LeBlanc A, Lu Y, Lang TF. Reduction in proximal femoral strength due to long-duration spaceflight. Bone. 2009;44:449-53.
221. Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F, Morandi L. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003;14:761-7. (Pubitemid 37295839)
222. Bikle DD, Halloran BP. The response of bone to unloading. J Bone Miner Metab. 1999;17:233-44.
223. Rucci N, Rufo A, Alamanou M, Teti A. Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio. J Cell Biochem. 2007;100:464-73. (Pubitemid 46146094)
224. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69:106-14. (Pubitemid 17030377)
225. Bertoni F, Present D, Enneking WF. Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am. 1985;67:890-900. (Pubitemid 15240314)
226. Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006;37:35-51. (Pubitemid 41719085)
227. Weber FP, Hutchison R, Macleod JJ. A case of multiple myeloma (myelomatosis) with bence-jones proteid in the urine (myelopathic albumosuria of Bradshaw, Kahler's Disease), and a summary of published cases of bence-jones albumosuria: with a report on the chemical pathology. Med Chir Trans. 1903;86:395-470.
228. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-87. (Pubitemid 37328787)
229. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998;82:1501-5. (Pubitemid 28164996)
230. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324-39.
231. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007;24:599-608. (Pubitemid 50003596)
232. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-64.
233. Granchi D, Corrias MV, Garaventa A, Baglio SR, Cangemi G, Carlini B, Paolucci P, Giunti A, Baldini N. Neuroblastoma and bone metastases: clinical significance and prognostic value of Dickkopf 1 plasma levels. Bone. 2011;48:152-9.
234. CLAIN A. Secondary malignant disease of bone. Br J Cancer. 1965;19:15-29.
235. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328:679-87. (Pubitemid 40208305)
236. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103:197-206. (Pubitemid 29053137)
237. Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem. 2008;8:342-9. (Pubitemid 351761438)
238. Buijs JT, Henriquez NV, van Overveld PG, van der Gabri H, ten Dijke P, Plicht G van der. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis. 2007;24:609-17. (Pubitemid 50003597)
239. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692-6.
240. Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res. 2010;70:6150-60.
241. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-93. (Pubitemid 37328925)
242. Silvestris F, Ciavarella S, De Matteo M, Tucci M, Dammacco F. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? Oncologist. 2009;14:264-75.
243. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005;23:8219-24. (Pubitemid 46211558)
244. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007;5:475-82.
245. Donath J, Krasznai M, Fornet B, Gergely P Jr, Poor G. Effect of bisphosphonate treatment in patients with Paget's disease of the skull. Rheumatology (Oxford). 2004;43:89-94. (Pubitemid 38088374)
246. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003;111:573-8. (Pubitemid 36330714)
247. Papapoulos SE. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Ann Med Interne. 2000;151:504-10.
248. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010;86:421-35.
249. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961-78. (Pubitemid 30413179)
250. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK, Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002;61:1255-62. (Pubitemid 34441791)
251. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581-9. (Pubitemid 28163009)
252. Marie PJ. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone. 2006;38:S10-4. (Pubitemid 43190768)
253. Blake GM, Fogelman I. Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy. Clin Interv Aging. 2006;1:367-75.
254. Caudrillier A, Hurtel-Lemaire AS, Wattel A, Cournarie F, Godin C, Petit L, Petit JP, Terwilliger E, Kamel S, Brown EM, Mentaverri R, Brazier M. Strontium ranelate decreases receptor activator of nuclear factor-KappaB ligand-induced osteoclastic differentiation in vitro: involvement of the calcium-sensing receptor. Mol Pharmacol. 2010;78:569-76.
255. Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update. 2000;6:419-26.
256. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 2000;106:1229-37.
257. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253-60. (Pubitemid 29358958)
258. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-29. (Pubitemid 36210865)
259. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst. 2001;93:1449-57. (Pubitemid 32982673)
260. Pageau SC. Denosumab. MAbs. 2009;1:210-5.
261. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007;9(Suppl 1):S7.
262. Ulrich-Vinther M, Schwarz EM, Pedersen FS, Soballe K, Andreassen TT. Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. Bone. 2005;37:751-8. (Pubitemid 41773484)
263. Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, Ominsky MS, Kostenuik PJ, Morgan EF, Einhorn TA. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009;24:196-208.
264. Geusens P. Emerging treatments for postmenopausal osteoporosis-focus on denosumab. Clin Interv Aging. 2009;4:241-50.
265. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010;6:325-43.
266. Gowen M. Inhibition of cathepsin K-a novel approach to antiresorptive therapy. Expert Opin Investig Drugs. 1997;6:1199-202. (Pubitemid 27395805)
267. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25:937-47.
268. Black WC, Bayly CI, Davis DE, Desmarais S, Falgueyret JP, Leger S, Li CS, Masse F, McKay DJ, Palmer JT, Percival MD, Robichaud J, Tsou N, Zamboni R. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005;15:4741-4. (Pubitemid 41354798)
269. Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009;18:585-600.
270. Lewiecki EM. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. IDrugs. 2009;12:799-809.
271. Perez-Castrillon JL, Pinacho F, De Luis D, Lopez-Menendez M, Duenas LA. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J Osteoporos. 2010.
272. Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece D, Iansante V, Zazzeroni F, Alesse E, Heinegard D, Teti A. The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell Biol. 2009;187:669-83.
273. Bengtsson E, Morgelin M, Sasaki T, Timpl R, Heinegard D, Aspberg A. The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor. J Biol Chem. 2002;277:15061-8. (Pubitemid 34952583)
274. Bengtsson E, Aspberg A, Heinegard D, Sommarin Y, Spillmann D. The amino-terminal part of PRELP binds to heparin and heparan sulfate. J Biol Chem. 2000;275:40695-702. (Pubitemid 32054886)
275. Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, Pierroz D, Morandi L, De Simone M, Rucci N, Bertini E, Bianchi ML, De Benedetti F, Teti A. Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res. 2011, in press.